Trial Profile

A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SYHX 1901 (Primary)
Indications Plaque psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors CSPC Ouyi Pharmaceutical

03 Jun 2021 Status changed from not yet recruiting to recruiting.
17 May 2021 New trial record
17 Mar 2021 According to a CSPC Pharmaceutical Group media release, the National Medical Products Administration has approved SYHX1901 for conducting clinical trials in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com